A method of cell culture termed organoid culture has been developed to expand tissue stem cells from various organs. In the recent Cell article, Huch, Gehart et al. applied organoid culture to cells derived from human liver, including from standard biopsies, to expand liver epithelial cells. 1 Cells grown as organoids could be massively expanded, remained genetically and phenotypically stable and could be differentiated into hepatocyte like cells. Cells expanded from patients with genetic liver diseases expressed the disease phenotype following differentiation. Organoid expansion was only successful using EpCAM positive biliary ductular cells rather than mature hepatocytes. This article is protected by copyright. All rights reserved.
(ESC) or induced pluripotent stem cell (iPSC) derived hepatocytes. 2, 3 However recent studies have raised concerns regarding the phenotypic maturity of these cells, 4 another lingering concern is their phenotypic and genetic stability and, consequently, their safety in vivo. This publication is therefore timely.
Leading up to this work has been an impressive series of observations in the field of adult stem cells.
Lgr5 is a cell marker that has been used to great effect to identify adult cells with stem cell like properties, initially in mouse gut but later in a variety of tissues. An important aspect that developed out of this work was the use of the organoid culture technique whereby stem cells could be expanded under the influence of Wnt signalling, whilst keeping some of their 3 dimensional cell-cell interactions. 4 This was first developed in the growth of gut organoids but was later applied to mouse liver where liver organoids could be grown from Lgr5+ epithelial cells isolated from adult mouse liver, and following expansion the cells could be differentiated into hepatocytes. This article is protected by copyright. All rights reserved.
Obviously for autologous therapy of genetic liver diseases of the hepatocyte some form of gene correction ex-vivo would be required. This has been previously tested using iPSCs derived hepatocytes derived from patients with alpha-1-antitrypsin (A1AT) deficiency. 
